Dry Eye Disease Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Dry Eye Disease market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Palatin Technologies, Novartis, Mc2 therapeutics, Hoffmann-La Roche, GlaxoSmithKline, MedImmune LLC, Aviceda Therapeutics, Inc., Eyestem Research Pvt. Ltd., Merck Sharp & Dohme LLC, Rigel Pharmaceuticals, Bristol-Myers Squibb, RemeGen Co., Ltd., and others..

[Nevada, United States] - DelveInsight's "Dry Eye Disease Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Dry Eye Disease, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Dry Eye Disease Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Dry Eye Disease Market Report:
The Dry Eye Disease market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In September, 2024: Novartis Pharmaceuticals announced that their study aims at elucidating the mechanism of action of ianalumab in salivary glands and explore relationships with clinical assessments
In September, 2024: Bristol-Myers Squibb announced that the purpose of their study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.
In September, 2024: IVIEW Therapeutics Inc. announced that a randomized (1:1:1), multicenter, parallel, vehicle-controlled, double-masked study to evaluate the safety, tolerability, and efficacy of IVW-1001 Ophthalmic Eyelid Wipes in subjects with DED.
In September, 2024: Huons Co., Ltd. announced a multicenter, Randomized, Double blind, Restasis®-controlled Non-inferiority, Moisview® Eye Drops Controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients with Dry Eye Syndrome
In September, 2024: Azura Ophthalmics announced a multicenter, double-masked, vehicle-controlled, randomized, parallel group study designed to evaluate the treatment of abnormal meibomian gland function and associated symptoms of DED using either AZR-MD-001 0.5% ophthalmic ointment or its vehicle. Study drug (either AZR-MD-001 or vehicle) will be dosed twice-weekly at bedtime for up to 12 months.
According to DelveInsight's analysis, the diagnosed prevalent cases of DED in the 7MM were over 54 million in 2023, these cases are expected to increase at a significant CAGR throughout the study period (2020-2034).
Japan accounted for nearly 11 million diagnosed prevalent cases of DED in 2023.These cases are expected to increase during the forecast period (2024-2034).
In 2023, the US had the highest number of diagnosed prevalent cases of DED among the 7MM, followed by Japan and the UK in the same year. These cases are expected to rise over the course of the study period from 2020 to 2034.
Key Dry Eye Disease Companies are as follows: Palatin Technologies, Novartis, Mc2 therapeutics, Hoffmann-La Roche, GlaxoSmithKline, MedImmune LLC, Aviceda Therapeutics, Inc., Eyestem Research Pvt. Ltd., Merck Sharp & Dohme LLC, Rigel Pharmaceuticals, Bristol-Myers Squibb, RemeGen Co., Ltd., and others..
Key Dry Eye Disease Therapies are as follow: CEQUA (cyclosporine ophthalmic solution) 0.09%, TYRVAYA (varenicline solution), Reproxalap, Tivanisiran (SYL1001), Tavilermide (MIM-D3), AR-15512, RP101, ECF843, diquafosol tetrasodium (INS365) Ophthalmic Solution, AR-15512, DE-101, Lifitegrast
Launching multiple stage Dry Eye Disease pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Dry Eye Disease market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Dry Eye Disease Overview:
Dry Eye Syndrome (DES) or Dry Eye Disease (DED) is characterized by chronic insufficient lubrication on the eye's surface, causing discomfort, irritation, and inflammation.

Dry Eye Disease Epidemiology Segmentation:
The Dry Eye Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Dry Eye Disease Gender-specific Diagnosed Prevalent Cases
Dry Eye Disease Age-specific Diagnosed Prevalent Cases
Dry Eye Disease Total Diagnosed Prevalent Cases
Dry Eye Disease Diagnosed Cases of Episodic and Chronic

For more information about Dry Eye Disease companies working in the treatment market, visit https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Dry Eye Disease Market Insights
Management of dry eye syndrome involves multiple approaches: over-the-counter artificial tears,prescription medications like RESTASIS or XIIDRA, procedures like LipiFlow, lifestyle changes such ashumidifier use and omega-3 supplements, and interventions like punctal plugs or scleral lenses for severecases. Early detection and proactive treatment can prevent complications like corneal ulcers and scarring.

Dry Eye Disease Drugs Uptake
CEQUA (cyclosporine ophthalmic solution) 0.09%is a sterile, clear solution indicated toincrease tear production in patients with keratoconjunctivitis sicca (dry eye), developedby Sun Pharmaceutical.
OYSTER POINT PHARMA introduces TYRVAYA (varenicline solution) nasal spray, aprescription treatment for DED. Administered twice daily, it leverages varenicline'sactivity at nicotinic acetylcholine receptors
EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%byAlcon LabsInc./Kala Pharmaceuticals is an FDA-approved treatment for short-term relief of dryeye disease symptoms.
VEVYE, by Novaliq/Harrow Eye, is a novel dry eye therapy containing cyclosporinesolubilized in a water-free excipient. FDA-approved in June 2023, it offers fast-actingrelief without water, antimicrobial preservatives, oils, or surfactants.
MIEBO (NOV03), developed by Bausch & Lomb Incorporated/Novaliq, is anFDAapproved (in 2023) water-free, preservative-free eye drop for dry eye disease associatedwith Meibomian gland dysfunction.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Dry Eye Disease Therapies and Key Companies:
CEQUA (cyclosporine ophthalmic solution) 0.09%: Sun Pharma
TYRVAYA (varenicline solution): Oyster Point Pharma
Reproxalap: Aldeyra Therapeutics, Inc.
Tivanisiran (SYL1001): Sylentis, S.A./PharmaMar
Tavilermide (MIM-D3): Mimetogen
AR-15512: Alcon/Aerie Pharmaceuticals
RP101: Redwood Pharma AB
ECF843: Novartis Pharmaceuticals
diquafosol tetrasodium (INS365) Ophthalmic Solution: Merck Sharp & Dohme LLC
AR-15512: Aerie Pharmaceuticals
DE-101: Santen Inc.
Lifitegrast: Shire

Dry Eye Disease Emerging Therapies:
PL9643 is a synthetic melanocortin receptor pan-agonist developed by Palatin Technologies, Inc. It targets inflammatory ocular conditions like dry eye disease by modulating the melanocortin receptor system.
Reproxalap, developed by Aldeyra Therapeutics, Inc., is an investigational new drug candidate in Phase III,targeting both dry eye disease and allergic conjunctivitis. It acts as a first-in-class small-molecule modulation of reactive aldehyde species (RASP), addressing inflammatory processes associated with ocular and systemic inflammatory diseases.
Tavilermide (MIM-D3) by Mimetogen is a small cyclic peptidomimetic drug that mimics nerve growth factor (NGF), currently in Phase III clinical development for treating DED. It acts as a partial TrkA receptor agonist, facilitating protein secretions from conjunctival glands and addressing multifactorial mechanisms of DED.
AR-15512, developed by Alcon/Aerie Pharmaceuticals, is a topical transient receptor potential melastatin8 (TRPM8) agonist aimed at treating the signs and symptoms of DED. Alcon plans to submit a New DrugApplication for AR-15512 to the FDA in mid-2024, indicating confidence in its therapeutic potential.
SkQ1 eye drops, developed by Mitotech, are mitochondria-targeted antioxidants designed to address dry eye disease through novel mechanisms at a cellular level.
BRM421, developed by BRIM Biotechnology, Inc., is a topical ophthalmic solution targeting moderate-to severe dry eye disease (DED).

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Dry Eye Disease Market Drivers:
Dry eye is a highly prevalent condition, affecting a significant portion of the population, particularly with advancing age. This prompts a substantial need for methods of diagnosis, treatment, and management solutions.
Various treatment options for dry eye syndrome are available, including artificial tears, prescription drugs, eyelid hygiene products, and punctal plugs, allowing for tailored approaches to management.

Dry Eye Disease Market Barriers:
Some dry eye treatments, particularly prescription medications, can have side effects like blurred vision or itching.
The cost of DED treatment, including prescription medications and frequent visits to healthcare providers, can be burdensome for patients.

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Dry Eye Disease Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Dry Eye Disease Companies: Palatin Technologies, Novartis, Mc2 therapeutics, Hoffmann-La Roche, GlaxoSmithKline, MedImmune LLC, Aviceda Therapeutics, Inc., Eyestem Research Pvt. Ltd., Merck Sharp & Dohme LLC, Rigel Pharmaceuticals, Bristol-Myers Squibb, RemeGen Co., Ltd., and others..
Key Dry Eye Disease Therapies: CEQUA (cyclosporine ophthalmic solution) 0.09%, TYRVAYA (varenicline solution), Reproxalap, Tivanisiran (SYL1001), Tavilermide (MIM-D3), AR-15512, RP101, ECF843, diquafosol tetrasodium (INS365) Ophthalmic Solution, AR-15512, DE-101, Lifitegrast
Dry Eye Disease Therapeutic Assessment: Current marketed and emerging therapies
Dry Eye Disease Market Dynamics: Dry Eye Disease Market drivers and Dry Eye Disease barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Dry Eye Disease Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Dry Eye Disease market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkprhttps://www.delveinsight.com/sample-request/dry-eye-disease-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Executive Summary of Dry Eye Disease
3. Competitive Intelligence Analysis for Dry Eye Disease
4. Dry Eye Disease: Market Overview at a Glance
5. Dry Eye Disease: Disease Background and Overview
6. Patient Journey
7. Dry Eye Disease Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Dry Eye Disease Unmet Needs
10. Key Endpoints of Dry Eye Disease Treatment
11. Dry Eye Disease Marketed Products
12. Dry Eye Disease Emerging Therapies
13. Dry Eye Disease: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Dry Eye Disease
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.